

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

CARTON BOX

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Leventa 1 mg/ml Oral Solution

2. STATEMENT OF ACTIVE SUBSTANCES

Each ml contains:

Levothyroxine sodium (as multihydrate) 1 milligram
(equivalent to 0.97 milligram levothyroxine)

3. PACKAGE SIZE

Carton box with one 30 ml bottle and one 1 ml oral dosing syringe.
Carton box with six 30 ml bottles and six 1 ml oral dosing syringes.
Carton box with twelve 30 ml bottles and twelve 1 ml oral dosing syringes.

4. TARGET SPECIES

Dogs.

5. INDICATIONS

6. ROUTES OF ADMINISTRATION

Oral use.

7. WITHDRAWAL PERIODS

8. EXPIRY DATE

Exp. {mm/yyyy}
Once opened, use within 6 months.

9. SPECIAL STORAGE PRECAUTIONS

Store in a refrigerator. Store in the original container.

10. THE WORDS "READ THE PACKAGE LEAFLET BEFORE USE"

Read the package leaflet before use.

11. THE WORDS "FOR ANIMAL TREATMENT ONLY"

For animal treatment only.

12. THE WORDS "KEEP OUT OF THE SIGHT AND REACH OF CHILDREN"

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Intervet International B.V.

14. MARKETING AUTHORISATION NUMBER

Vm 06376/5058
Vm 06376/3058

15. BATCH NUMBER

Lot {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING
UNITS**

BOTTLE- 30 ml

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Leventa

2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

Each ml contains:

Levothyroxine sodium (as multihydrate) 1 milligram
(equivalent to 0.97 milligram levothyroxine)

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}
Once opened, use within 6 months.
Once opened, use by:...

PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Leventa 1 mg/ml Oral Solution for Dogs

2. Composition

Each ml contains:

Active substances:

Levothyroxine sodium (as multihydrate)	1 milligram
(equivalent to 0.97 milligram levothyroxine)	

Excipients:

Ethanol 96%	0.15 ml
-------------	---------

Clear colourless to slight reddish solution.

3. Target species

Dogs.

4. Indications for use

Treatment of hypothyroidism in dogs.

5. Contraindications

Do not use in dogs with hyperthyroidism or uncorrected adrenal insufficiency (hypoadrenocorticism).

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

6. Special warnings

Special precautions for safe use in the target species:

The veterinary medicinal product should be used with caution in dogs with cardiac disease, diabetes mellitus or treated adrenal insufficiency (hypoadrenocorticism). For these dogs, gradual introduction of levothyroxine therapy, starting with 25 % of the

normal dose and increasing by 25 % increments every two weeks until optimal stabilisation is achieved is recommended.

The clinical diagnosis of hypothyroidism should be confirmed by laboratory tests.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician. Note: this veterinary medicinal product contains a high concentration of

L-thyroxine sodium and may present a risk to humans if ingested.

Wash hands after use.

In case of eye contact, flush immediately with water.

Pregnancy and lactation:

The safety of the veterinary medicinal product has not been established during pregnancy.

However, thyroxine is essential for normal foetal development. Hypothyroidism during pregnancy may be associated with impaired cognitive development and increased foetal mortality. During pregnancy, maternal thyroid hormone requirements may increase. Pregnant bitches receiving treatment should therefore be monitored on a regular basis from conception until several weeks after delivery, as dose requirements may change during pregnancy and lactation.

Use in lactating bitches or animals intended for future breeding has not been evaluated.

Interaction with other medicinal products and other forms of interaction:

L-thyroxine absorption may be impaired by the concomitant administration of antacids, e.g. aluminium or magnesium salts or calcium carbonate, or ferrous sulphate, and sucralfate. Therefore, concomitant administration of veterinary medicinal product with the above mentioned compounds should be avoided. At least 2 hours should elapse between administration of veterinary medicinal product and such products.

The therapeutic response to veterinary medicinal product may be altered by any compound that influences thyroid hormone metabolism and disposition (e.g. drugs displacing protein-binding site, modifying serum thyroxine-binding globulin concentration, or altering hepatic degradation of thyroxine or peripheral conversion of thyroxine to triiodothyronine). Thus, in case of concomitant administration of veterinary medicinal product with a compound exhibiting one of these properties, it is recommended to recheck that thyroid hormone concentrations are appropriate and to adjust the dose of veterinary medicinal product accordingly if needed.

Conversely, L-thyroxine supplementation may affect the pharmacokinetics and activity of concurrent therapies. In diabetic dogs treated with insulin, L-thyroxine supplementation may alter insulin requirements. In dogs with cardiac insufficiency, therapeutic response to cardiac glycosides may be decreased by L-thyroxine supplementation. Therefore, if treated with any of these compounds, dogs should be monitored carefully during initiation of treatment with veterinary medicinal product.

Please inform your veterinary surgeon if your dog receives any other medication before or during treatment with the veterinary medicinal product.

Overdose:

Clinical signs of overdose with L-thyroxine are identical to those of hyperthyroidism and include body weight loss, hyperactivity, tachycardia, polydipsia, polyuria, polyphagia and diarrhoea. These signs are generally mild and fully reversible. Overdose may be accompanied by reversible changes in blood biochemistry, e.g. elevated glucose, inorganic phosphorus and albumin: globulin ratio, and reduced total protein and cholesterol.

In a tolerance study, healthy dogs treated with the veterinary medicinal product at 40 µg/kg body weight once daily during 91 consecutive days did not present any relevant clinical sign. At dose rates of 120 and 200 µg/kg body weight, dogs did not exhibit signs other than those of hyperthyroidism, mainly body weight loss. These signs were mild and reversible, with recovery occurring within 5 weeks after cessation of treatment.

Standard measures should be taken to remove non-absorbed drug from the gastrointestinal tract.

If chronic overdosage is suspected, the dose should be re-evaluated.

Major incompatibilities:

None known.

7. Adverse events

Dogs:

Rare (1 to 10 animals / 10,000 animals treated):	Weight loss, polydipsia (increased thirst) Polyuria (excessive urination) Hyperactivity Vomiting, diarrhoea.
Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Polyphagia (increased hunger) Tachycardia (fast heart rate) Skin reaction (e.g. scale ¹) ² .

¹ Mild to moderate.

² Transient and self-resolving.

Adverse reactions associated with treatment with L-thyroxine sodium are primarily those of hyperthyroidism due to therapeutic overdose.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder

using the contact details at the end of this leaflet, or via your national reporting system:

Website: <https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine>

e-mail: adverse.events@vmd.gov.uk

8. Dosage for each species, routes and method of administration

Oral use.

In thyroid hormone replacement therapy with L-thyroxine, the dose rate and regime have to be tailored individually to each dog. A starting dose rate of 20 microgram L- thyroxine sodium/kg (0.2 ml per 10 kg bodyweight) once daily is recommended. Four weeks later, dose adjustment should be performed based on the clinical response to treatment and thyroid hormone concentration evaluated 4-6 hours after administration of the veterinary medicinal product. Further assessment of hormonal responses and dose adjustment may be repeated at 4 week intervals if required.

A maintenance dose rate between 10 and 40 microgram/kg body weight once daily is generally sufficient. The dosage suitable to treat your dog is decided by your prescribing veterinarian. Depending on the dosage and on the body weight of your dog, the volume (in ml) of the veterinary medicinal product to be administered once daily can be estimated using the following table:

Body weight (kg)	Dosage (microgram/kg)			
	10	20	30	40
	Volume of the veterinary medicinal product (ml)			
5	0.05	0.10	0.15	0.20
10	0.10	0.20	0.30	0.40
15	0.15	0.30	0.45	0.60
20	0.20	0.40	0.60	0.80
25	0.25	0.50	0.75	1.00
30	0.30	0.60	0.90	1.20
35	0.35	0.70	1.05	1.40
40	0.40	0.80	1.20	1.60
45	0.45	0.90	1.35	1.80
50	0.50	1.00	1.50	2.00

The dose for dogs weighing more than 50 kg should be calculated according to bodyweight in the same way.

Once a suitable dose rate and regime have been established, it is recommended to recheck every 6 months that thyroid hormone concentrations are appropriate.


Metabolic signs such as lethargy usually improve within two weeks after the onset of treatment whereas skin and coat changes may require 6 weeks or more of treatment before improvement is seen.

9. Advice on correct administration

The veterinary medicinal product should be administered at the same time every day. The absorption of L- thyroxine is influenced by food. Thus, L-thyroxine should be preferably administered 2-3 hours prior to feeding. If not, the feed given (type and amount) should be standardized.

Instruction for use of the oral syringe:

Open the bottle. (1) Attach the dosing syringe to the bottle by gently pushing the end of the syringe onto the insert in the bottle. (2) Turn the bottle/syringe upside down and draw the solution into the syringe by pulling the plunger out until the edge of the ring on the end of the plunger coincides with the expected volume or body weight in kilograms. (3) Turn the bottle/syringe right way up and remove the syringe from the insert. (4) After administering the veterinary medicinal product, (5) clean the syringe by flushing with clean water and allow to dry naturally.



10. Withdrawal periods

Not applicable.

11. Special storage precautions

Keep out of the sight and reach of children.

Store in a refrigerator (2 °C - 8 °C). Store in the original container.

Shelf life after first opening the immediate packaging: 6 months.

Do not use this veterinary medicinal product after the expiry date which is stated on the label after Exp. The expiry date refers to the last day of that month.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with

any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. Marketing authorisation numbers and pack sizes

Vm 06376/5058
Vm 06376/3058

Carton box with one 30 ml bottle and one 1 ml oral dosing syringe.
Carton box with six 30 ml bottles and six 1 ml oral dosing syringes.
Carton box with twelve 30 ml bottles and twelve 1 ml oral dosing syringes.
Not all pack sizes may be marketed.

15. PID LINK (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

16. Contact details

Marketing authorisation holder:

Intervet International B.V.
Wim de Körverstraat 35
5831 AN Boxmeer
Netherlands

Manufacturers responsible for batch release:

Intervet Productions
Rue de Lyons
27460 Igoville
France

Contact details to report suspected adverse reactions:

UK(GB)

MSD Animal Health UK Ltd.
Tel.: +44 (0)1908 685685

UK(NI)

Intervet Ireland Ltd.
Tel.: +353 (0)1 2970220

Local representative:

MSD Animal Health UK Limited
Walton Manor, Walton
Milton Keynes
MK7 7AJ
United Kingdom

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

17. Other information

POM-V

Gavin Hall
Approved: 26 September 2025